(0.00%) 5 187.67 points
(0.44%) 39 056 points
(-0.18%) 16 303 points
(0.30%) $79.23
(-0.50%) $2.18
(-0.25%) $2 316.50
(-0.09%) $27.58
(0.07%) $985.30
(0.02%) $0.930
(0.06%) $10.90
(0.01%) $0.800
(0.01%) $91.75
Live Chart Being Loaded With Signals
Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration...
Stats | |
---|---|
今日成交量 | 23 644.00 |
平均成交量 | 13 379.00 |
市值 | 0.00 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -2.56 |
ATR14 | €0 (0.00%) |
GenKyoTex SA 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
GenKyoTex SA 财务报表
Annual | 2020 |
营收: | €0.00 |
毛利润: | €0.00 (0.00 %) |
EPS: | €-1.197 |
FY | 2020 |
营收: | €0.00 |
毛利润: | €0.00 (0.00 %) |
EPS: | €-1.197 |
FY | 2019 |
营收: | €0.00 |
毛利润: | €0.00 (0.00 %) |
EPS: | €-0.839 |
FY | 2018 |
营收: | €794 000 |
毛利润: | €794 000 (100.00 %) |
EPS: | €-1.430 |
Financial Reports:
No articles found.
GenKyoTex SA
Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。